composition;

(c) a hydrophilic polymer comprising a controlled particle size in the drug composition;

(d) a means for delaying release of drug from the drug composition.

40 ~~45~~. The dosage form of Claim 39 ~~44~~ wherein the drug is verapamil hydrochloride.

41 ~~46~~. The dosage form of Claim 39 ~~44~~ wherein the drug possesses a controlled particle size of up to 150 μm and the hydrophilic polymer possesses a controlled particle size of up to 250 μm.

42 ~~47~~. A method for the manufacture of a dosage form adapted to release a drug at a rate having a percentage deviation of not more than 5% from a mean release rate over a prolonged period of time comprising:

(a) controlling a drug particle size;

(b) controlling a hydrophilic polymer particle size;

(c) admixing the drug with the hydrophilic polymer;

(d) providing a means for prolonging release of the drug.

43 ~~48~~. A method for the manufacture of a dosage form according to claim 42 ~~47~~ wherein the drug is verapamil hydrochloride.

44
~~49~~. A method for the manufacture of a dosage form according to claim 42 ~~47~~ wherein the prolonged release is four hours or more.

45
~~50~~. A method for the manufacture of a dosage form according to claim 42 ~~47~~ wherein the drug particle size is controlled to up to 150 μm, and the hydrophilic polymer particle size is controlled to up to 250 μm.

46
~~51~~. A method for maintaining a percentage deviation in a drug release rate of not more than 5% from the mean release rate over a prolonged period of time comprising:

(a) controlling a drug particle size;

(b) controlling a hydrophilic polymer particle size;

(c) admixing the drug with the hydrophilic polymer;

(d) providing a means for prolonging release of the drug.

47
~~52~~. A method for providing a controlled drug rate of release from a dosage form in a patient, wherein the method comprises:

(a) admitting orally into the patient a therapeutic composition comprising a dose of drug with the drug possessing a controlled particle size, and a hydrophilic polymer for the drug possessing a controlled particle size; and

(b) codelivering the drug and the accompanying hydrophilic polymer at a substantially constant rate of release from the composition to provide an effective therapeutic dose in the patient.

48
~~58.~~ The method for providing a controlled drug rate of release from a dosage form in a patient according to claim ~~52~~ 47, wherein the substantially constant rate of release from the composition has a percentage deviation of not more than 5% from the mean release rate over a prolonged period of time.

49
~~54.~~ The method for providing a controlled drug rate of release from a dosage form in a patient according to claim ~~53~~ 48, wherein the prolonged period of time is four hours or more.

50
~~55.~~ The method for providing a controlled drug rate of release from a dosage form in a patient according to claim ~~52~~ 47, wherein the controlled particle size of the drug is up to 150 μm, and the controlled particle size of the hydrophilic polymer is up to 250 μm.

51
~~56.~~ A method for providing a rate of release from a dosage form in a patient having a percentage deviation of not more than 5% from the mean release rate over a prolonged period of time, wherein the method comprises:

(a) admitting orally into the patient a therapeutic composition comprising a

(a) admitting orally into the patient a therapeutic composition comprising a dose of drug with the drug possessing a controlled particle size, and a hydrophilic polymer possessing a controlled particle size; and

(b) codelivering the drug and the accompanying hydrophilic polymer at a substantially constant rate of release from the composition to provide an effective therapeutic dose in the patient.

52
~~57.~~ The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 51, wherein the prolonged period of time is four hours or more.

53
~~58.~~ The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 51, wherein the drug possesses a controlled particle size of up to 150 μm, and the hydrophilic polymer possesses a controlled particle size of up to 250 μm.

REMARKS

Claims 1-43 are cancelled without prejudice.

Claims 44-58 were added.

Attached hereto is a clean copy of the changes made to the claims by the current amendment. The attached page is captioned **"Clean Copy of Claims."**